Videau D, Niel G, Siboulet A, Catalan F
Br J Vener Dis. 1978 Apr;54(2):77-80. doi: 10.1136/sti.54.2.77.
The therapeutic activity of a single 2 g dose of secnidazole was studied in patients with urogenital trichomoniasis. In 140 patients, 97% were cured and the drug was well tolerated. In the laboratory, tests on sensitivity were made and the minimal inhibitory concentration (MIC) and the minimal trichomonacidal concentration (MTC) were determined on cultures that had recently been isolated at the clinic, and the pharmacokinetic properties of secnidazole in man were compared with those of tinidazole. The therapeutic efficacy of all the metronidazole derivatives was reviewed and a single-dose treatment is recommended. Therapeutic and prophylactic treatment is achieved by products with a long half-life. Secnidazole, with a half-life of 14.3 +/- 1.3 h (women) and 20.2 +/- 3.1 h (men), is particularly suitable for this type of treatment.
对2克单剂量的塞克硝唑治疗泌尿生殖系统滴虫病患者的疗效进行了研究。在140名患者中，97%得到治愈，且该药物耐受性良好。在实验室中，进行了敏感性测试，并对近期从诊所分离出的培养物测定了最低抑菌浓度（MIC）和最低杀滴虫浓度（MTC），还将塞克硝唑在人体中的药代动力学特性与替硝唑进行了比较。对所有甲硝唑衍生物的治疗效果进行了综述，并推荐单剂量治疗。具有长半衰期的产品可实现治疗和预防作用。半衰期为14.3±1.3小时（女性）和20.2±3.1小时（男性）的塞克硝唑特别适合此类治疗。
